| Autor: |
Kimberlin, David W., Acosta, Edward P., Prichard, Mark N., Sánchez, Pablo J., Ampofo, Krow, Lang, David, Ashouri, Negar, Vanchiere, John A., Abzug, Mark J., Abughali, Nazha, Caserta, Mary T., Englund, Janet A., Sood, Sunil K., Spigarelli, Michael G., Bradley, John S., Lew, Judy, Michaels, Marian G., Wan, Wen, Cloud, Gretchen, Jester, Penelope |
| Předmět: |
|
| Zdroj: |
Journal of Infectious Diseases; Mar2013, Vol. 207 Issue 5, p709-720, 12p |
| Abstrakt: |
Background. Children <2 years of age are at high risk of influenza-related mortality and morbidity. However, the appropriate dose of oseltamivir for children <2 years of age is unknown.Methods. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group evaluated oseltamivir in infants aged <2 years in an age–de-escalation, adaptive design with a targeted systemic exposure.Results. From 2006 to 2010, 87 subjects enrolled. An oseltamivir dose of 3.0 mg/kg produced drug exposures within the target range in subjects 0–8 months of age, although there was a greater degree of variability in infants <3 months of age. In subjects 9–11 months of age, a dose of 3.5 mg/kg produced drug exposures within the target range. Six of 10 subjects aged 12–23 months receiving the Food and Drug Administration–approved unit dose for this age group (ie, 30 mg) had oseltamivir carboxylate exposures below the target range. Virus from 3 subjects developed oseltamivir resistance during antiviral treatment.Conclusions. The appropriate twice-daily oral oseltamivir dose for infants ≤8 months of age is 3.0 mg/kg, while the dose for infants 9–11 months old is 3.5 mg/kg.Clinical Trials Registration. NCT00391768. [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
